Skip to main content
Erschienen in:

12.12.2024 | Rektumkarzinom | Fortbildung

Operative und neoadjuvante Therapieoptionen

Neue Konzepte beim Rektumkarzinom

verfasst von: PD Dr. med. Christian Peter Pox

Erschienen in: Gastro-News | Ausgabe 6/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Für die Behandlung eines Rektumkarzinoms gibt es mittlerweile eine Vielzahl an Behandlungsmöglichkeiten. So kann beispielsweise auf eine Operation verzichtet werden, wenn sich schon durch eine neoadjuvante Therapie eine vollständige Remission einstellt. Allerdings ist eine regelmäßige Nachsorge notwendig, um Lokalrezidive rechtzeitig zu erkennen.
Literatur
1.
Zurück zum Zitat Zwager L, Bastiaansen B, Montazeri N et al. Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis. Gastroenterology. 2022;163:174-89 Zwager L, Bastiaansen B, Montazeri N et al. Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis. Gastroenterology. 2022;163:174-89
2.
Zurück zum Zitat Jayne DG, Thorpe HC, Copeland J et al. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg. 2010;97:1638-45 Jayne DG, Thorpe HC, Copeland J et al. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg. 2010;97:1638-45
3.
Zurück zum Zitat Des Guetz G, Landre T, Bollet MA et al. Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis. Cancer. 2021;13:6035 Des Guetz G, Landre T, Bollet MA et al. Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis. Cancer. 2021;13:6035
4.
Zurück zum Zitat Tamburini E, Tassinari D, Ramundo M et al. Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2022;172:103627 Tamburini E, Tassinari D, Ramundo M et al. Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2022;172:103627
5.
Zurück zum Zitat Bahadoer RR, Dijkstra EA, van Etten B et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29-42 Bahadoer RR, Dijkstra EA, van Etten B et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29-42
6.
Zurück zum Zitat Bahadoer RR, Hospers GA, Marijnen CA et al. Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial. Eur J Cancer. 2023;185:139-49 Bahadoer RR, Hospers GA, Marijnen CA et al. Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial. Eur J Cancer. 2023;185:139-49
7.
Zurück zum Zitat Conroy T, Bosset JF, Etienne PL et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702-15 Conroy T, Bosset JF, Etienne PL et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702-15
8.
Zurück zum Zitat Conroy T, Castan F, Etienne PL et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35:873-81 Conroy T, Castan F, Etienne PL et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35:873-81
9.
Zurück zum Zitat Garcia-Aguilar J, Patil S, Gollub MJ et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol .2022;40:2546-56 Garcia-Aguilar J, Patil S, Gollub MJ et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol .2022;40:2546-56
10.
Zurück zum Zitat Fokas E, Schlenska-Lange A, Polat B et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022;8:e215445 Fokas E, Schlenska-Lange A, Polat B et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022;8:e215445
11.
Zurück zum Zitat Fernandez LM, Sao Juliao GP, Figueiredo NL et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43-50 Fernandez LM, Sao Juliao GP, Figueiredo NL et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43-50
12.
Zurück zum Zitat Cercek A, Lumish M, Sinopoli J et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386:2363-76 Cercek A, Lumish M, Sinopoli J et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386:2363-76
13.
Zurück zum Zitat Ruppert R, Junginger T, Kube R et al. Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study. J Clin Oncol. 2023;41:4025-34 Ruppert R, Junginger T, Kube R et al. Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study. J Clin Oncol. 2023;41:4025-34
Metadaten
Titel
Operative und neoadjuvante Therapieoptionen
Neue Konzepte beim Rektumkarzinom
verfasst von
PD Dr. med. Christian Peter Pox
Publikationsdatum
12.12.2024

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?